Revance Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	-	-	-	0.07	0.2
Other Revenue	0.06	0.3	0.2	0.02	0.01
Revenue	0.06	0.3	0.2	0.1	0.21
Revenue Growth (YoY)	-85.17%	52.07%	106.10%	-54.09%	-
Cost of Revenue	2.13	2.96	2.25	2.27	0.71
Gross Profit	-2.07	-2.66	-2.06	-2.17	-0.5
Selling, General & Admin	1.18	1.24	1.02	0.87	0.39
Other Operating Expenses	0.02	0.02	0.06	0.02	0.01
Operating Expenses	1.47	1.56	1.19	1.04	0.49
Operating Income	-3.53	-4.23	-3.24	-3.21	-0.99
Interest Expense	-0.12	-0.25	-0.07	-0.01	-0.07
Interest & Investment Income	0.09	0.09	0.07	0.01	0.01
Other Non Operating Income (Expenses)	-0	-	0	0	-
EBT Excluding Unusual Items	-3.56	-4.39	-3.24	-3.21	-1.05
Other Unusual Items	-0	-0.01	0.01	0	0.06
Pretax Income	-3.57	-4.4	-3.23	-3.21	-0.99
Income Tax Expense	-0.43	-0.44	-0.48	-0.56	-0.2
Net Income	-3.13	-3.96	-2.75	-2.65	-0.79
Net Income to Common	-3.13	-3.96	-2.75	-2.65	-0.79
Shares Outstanding (Basic)	5	5	4	4	3
Shares Outstanding (Diluted)	5	5	4	4	3
Shares Change (YoY)	16.20%	12.99%	0.52%	33.59%	-
EPS (Basic)	-0.61	-0.80	-0.63	-0.61	-0.24
EPS (Diluted)	-0.61	-0.80	-0.63	-0.61	-0.24
Gross Margin	-	-	-	-	-238.46%
Operating Margin	-5549.18%	-1409.62%	-1644.00%	-3358.25%	-473.81%
Profit Margin	-4924.73%	-1319.68%	-1393.30%	-2764.69%	-379.43%
EBITDA	-3.26	-3.93	-3.14	-3.06	-0.89
D&A For EBITDA	0.27	0.3	0.1	0.16	0.09
EBIT	-3.53	-4.23	-3.24	-3.21	-0.99
Revenue as Reported	0.06	0.3	0.2	0.1	0.21

Source: S&P Global Market Intelligence. Standard template. Financial Sources.